Vasalgel highlighted in NYT debate

What better way to start the New Year than informing the public about the importance of male contraception? Elaine Lissner, Director of Parsemus Foundation and the Male Contraception Information Project, provided input for the New York Times “Room for Debate” piece on Thinking Beyond the Pill. Along with four other panelists discussing the issues of birth control, Lissner provided a cogent call to action to provide support for advanced male contraceptive options. She notes “The pipeline is already full, and if we’re serious about wanting new choices, we need to finish the work that has been started, not do more basic research.” With Vasalgel entering the final stages of preclinical testing, it is likely the product that will actually make it to market in the US in the next couple of years.

Linda Brent, PhD

Executive Director, Parsemus Foundation

Tell us what you think

This form does not collect your email address. If you would like us to respond, please send questions to info@parsemus.org.
This field is for validation purposes and should be left unchanged.
We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today